May 17, 1992 |
For many Orange County executives, 1991 was a year when their pay packages came under greater shareholder scrutiny and corporate boards were cautious in handing out cash bonuses and perks. It mirrored a trend statewide of keeping executive compensation in line with a company's financial performance. Of the top 100 county executives on the list of publicly traded companies, one-third of the officers saw their cash compensation remain unchanged or had it reduced.
September 9, 1995
Bergen Brunswig's president and chief operating officer Dwight Steffensen has resigned, the pharmaceuticals supplier said Friday. Steffensen's resignation will become effective in mid-October, but he will remain on the board. The company said Steffensen, who joined the company in 1985 and became president in 1992, is leaving to pursue other opportunities. Robert E. Martini, chairman and chief executive, will assume Steffensen's duties next month until a successor is named.
October 4, 2000 |
Bergen Brunswig Corp., the nation's third-largest distributor of pharmaceuticals and medical supplies, said Tuesday that James R. Mellor was named chairman of the board's executive committee. The company, based in Orange, said in a press release that the executive committee exercises corporate oversight when the board is not in session. Mellor, a director since 1979, replaces Robert E. Martini as head of the executive committee.
November 1, 1996
Bergen Brunswig Corp. posted record earnings and revenue for the fiscal year ended Sept. 30, the distributor of pharmaceuticals and medical surgical supplies said Thursday. Net income rose 15.6% to $73.9 million, or $1.83 per share, from $63.9 million, or $1.61 per share, for the previous year. Revenue climbed nearly 18%, outpacing the company's top two competitors, said Robert E. Martini, chairman and chief executive. Revenue totaled $9.9 billion, up from $8.4 billion.
January 18, 1992
Bergen Brunswig Corp. announced Friday that its drug distribution subsidiary has agreed to acquire the pharmaceutical distribution assets of Owens & Minor Inc. for about $50 million in cash. The acquisition, expected to close in late February after regulatory and other approvals, will allow Bergen Brunswig Drug Co. to extend its distribution network from Virginia into the mid-Atlantic states and to quadruple its annual sales from $100 million to $400 million, said Robert E.